Oppenheimer & CO Inc Outlook Therapeutics, Inc. Transaction History

Oppenheimer & CO Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.22 - $0.66 $770 - $2,310	-3,500 Reduced 14.23%	21,100 $8,000
Q3 2023 Nov 07, 2023	BUY	$0.2 - $1.78 $2,200 - $19,580	11,000 Added 80.88%	24,600 $5,000
Q2 2023 Aug 02, 2023	SELL	$1.02 - $1.89 $9,384 - $17,388	-9,200 Reduced 40.35%	13,600 $23,000
Q1 2023 May 10, 2023	BUY	$1.0 - $1.35 $500 - $675	500 Added 2.24%	22,800 $24,000
Q4 2022 Feb 07, 2023	BUY	$0.87 - $1.33 $3,741 - $5,719	4,300 Added 23.89%	22,300 $24,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $4,080 - $5,040	4,000 Added 28.57%	18,000 $22,000
Q2 2022 Aug 08, 2022	BUY	$0.91 - $2.01 $12,740 - $28,139	14,000 New	14,000 $14,000
Q1 2022 May 12, 2022	SELL	$1.22 - $2.03 $26,962 - $44,862	-22,100 Closed	0 $0
Q4 2021 Feb 02, 2022	BUY	$1.27 - $2.23 $11,684 - $20,516	9,200 Added 71.32%	22,100 $30,000
Q3 2021 Nov 12, 2021	SELL	$2.12 - $2.76 $1,484 - $1,931	-700 Reduced 5.15%	12,900 $28,000
Q2 2021 Aug 03, 2021	BUY	$1.78 - $2.76 $890 - $1,380	500 Added 3.82%	13,600 $34,000
Q1 2021 May 10, 2021	BUY	$0.94 - $3.31 $12,314 - $43,361	13,100 New	13,100 $29,000
Q4 2020 Feb 11, 2021	SELL	$0.7 - $1.58 $7,000 - $15,800	-10,000 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$0.61 - $1.6 $6,100 - $16,000	10,000 New	10,000 $7,000
Q2 2020 Aug 11, 2020	SELL	$0.56 - $1.41 $6,440 - $16,214	-11,500 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$0.51 - $1.08 $5,865 - $12,420	11,500 New	11,500 $7,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.21B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.